Protego Biopharma Secures $130 Million to Propel AL Amyloidosis Research Forward Protego Biopharma has raised $130 million in an oversubscribed Series B funding round, aiming to advance its groundbreaking therapy for AL amyloidosis into pivotal clinical trials.

Protego Biopharma Secures $130 Million to Propel AL Amyloidosis Research Forward #USA #San_Diego #AL_Amyloidosis #Protego_Biopharma #PROT-001